Crohn Disease Clinical Trials in Los Angeles, California

10 studies are recruiting for crohn disease in Los Angeles, California right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease

   Study IIBD is a master protocol that will support a collection of individual sub studies that share key design components. Participants will be assigned to the appropriate study prior to randomization to a treatment group. The studies aim to evaluate the efficacy and safety of new treatments in adu…

   Stage

   Phase 2

   Ages

   18 to 80

   Site

   Biopharma Informatic, LLC, Los Angeles, California

   Locations

   70 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07483073 on ClinicalTrials.gov

2. A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease

   The main purpose of this study is to see how the safety and efficacy of a farnesoid X receptor (FXR) agonist (LY4395089), given together with mirikizumab compares with mirikizumab (alone) in adults with moderately to severely active Crohn's disease (CD). This study is part of the IIBD master protoc…

   Stage

   Phase 2

   Ages

   18 to 80

   Site

   Biopharma Informatic, LLC, Los Angeles, California

   Locations

   70 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07483099 on ClinicalTrials.gov

3. A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease

   The purpose of this study is to evaluate how-well icotrokinra works (clinical efficacy) and how safe it is (safety) in participants with moderately to severely active Crohn's disease (CD; a long-term condition causing severe inflammation of the intestinal tract).

   Stage

   Phase 2

   Ages

   18 and older

   Site

   TLC Clinical Research Inc, Los Angeles, California

   Locations

   370 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT07196722 on ClinicalTrials.gov

4. A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease

   The purpose of this study is to assess how well guselkumab works when compared to risankizumab in participants with moderately to severely active Crohn's Disease (CD; a long-term condition causing severe inflammation of the intestinal tract).

   Stage

   Phase 3

   Ages

   18 and older

   Site

   TLC Clinical Research Inc, Los Angeles, California

   Locations

   160 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT07499232 on ClinicalTrials.gov

5. Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission

   The purpose of this study is to compare the effectiveness and safety of a strategy of switching to an alternative targeted immunomodulator (TIM) therapy to treat to a target of endoscopic remission, versus continuing index TIM in patients with inflammatory bowel disease (IBD) (Crohn's disease or ul…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Cedars-Sinai, Los Angeles, California

   Locations

   24 in total

   Run by

   Mayo Clinic

   See if you can join NCT05230173 on ClinicalTrials.gov

6. Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease

   Crohn's disease (CD) is a condition that causes inflammation (swelling, redness) of the lining and wall of the small intestine, large intestine, or both. CD may be associated with abdominal cramps/pain, diarrhea, blood in the stool, weight loss, or delayed growth in children. While the exact cause …

   Stage

   Phase 4

   Ages

   6 to 17

   Site

   Cedars-Sinai, Los Angeles, California

   Locations

   26 in total

   Run by

   Connecticut Children's Medical Center

   See if you can join NCT05781152 on ClinicalTrials.gov

7. Precise Infliximab Exposure and Pharmacodynamic Control

   Approximately 3 million people in the United States are living with inflammatory bowel disease, which includes Crohn's Disease (CD). There are limited treatment options approved for use in children and adults with Crohn's disease. Physicians need better ways to inform decisions on treatment. The ma…

   Stage

   Phase 2

   Ages

   6 to 22

   Site

   Children's Hospital of Los Angeles, Los Angeles, California

   Locations

   11 in total

   Run by

   Children's Hospital Medical Center, Cincinnati

   See if you can join NCT05660746 on ClinicalTrials.gov

8. Impact of Prebiotics in Ulcerative Colitis

   The cause of inflammatory bowel disease (IBD) is currently unknown, although partly attributed to interactions among genetic risk polymorphisms, environmental factors, gut microbiome, and host immunity. Diet, particularly those with plant-based products, have been shown in prior research to improve…

   Stage

   Not phased

   Ages

   18 to 85

   Site

   UCLA, Los Angeles, California

   Run by

   University of California, Los Angeles

   See if you can join NCT06495658 on ClinicalTrials.gov

9. Stem Cell Transplantation in Crohn's Disease

   Unfortunately, some patients with Crohn's disease (CD) fail to respond to the best clinical treatments and some only experience temporary benefit. For severe Crohn's disease, there is an experimental treatment called "high dose immunoablation" followed by autologous hematopoietic stem cell transpla…

   Stage

   Phase 1

   Ages

   13 to 28

   Site

   Cedars-Sinai Medical Center, Los Angeles, California

   Run by

   Cedars-Sinai Medical Center

   See if you can join NCT04224558 on ClinicalTrials.gov

10. VECTORS - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease

    Transmural healing (TMH) is recognized as a potentially important measure of Crohn's disease (CD) activity but not a formal target. Observational studies suggest that TMH may be associated with better long-term outcomes. The study will evaluate TMH using noninvasive intestinal ultrasound (IUS), a p…

    Stage

    Phase 4

    Ages

    18 to 80

    Site

    TLC Clinical Research Inc - Los Angeles, Los Angeles, California

    Locations

    69 in total

    Run by

    Alimentiv Inc.

    See if you can join NCT06257706 on ClinicalTrials.gov